AARD (Aardvark Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Aardvark Therapeutics, Inc. Common Stock (AARD) is a publicly traded Healthcare sector company. As of May 21, 2026, AARD trades at $4.43 with a market cap of $95.12M and a P/E ratio of -1.33. AARD moved -1.49% today. Year to date, AARD is -67.70%; over the trailing twelve months it is -61.00%. Its 52-week range spans $3.35 to $19.58. Analyst consensus is buy with an average price target of $15.14. Rallies surfaces AARD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate AARD?

10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, and 0 strong sell. The consensus rating is buy. The average price target is $15.14.

AARD Key Metrics

Key financial metrics for AARD
MetricValue
Price$4.43
Market Cap$95.12M
P/E Ratio-1.33
EPS$-3.21
Dividend Yield0.00%
52-Week High$19.58
52-Week Low$3.35
Volume153.21K
Avg Volume0
Revenue (TTM)$-1.18M
Net Income$-69.87M
Gross Margin0.00%

AARD Analyst Consensus

10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.14.

Latest AARD News

Recent AARD Insider Trades

  • Sun Nelson bought 3.00K (~$43.20K) on Dec 11, 2025.
  • Lee Tien-Li bought 7.00K (~$101.39K) on Dec 11, 2025.
  • Lee Tien-Li bought 6.50K (~$61.82K) on Sep 15, 2025.

Common questions about AARD

What do analysts rate AARD?
10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, and 0 strong sell. The consensus rating is buy. The average price target is $15.14.
Does Rallies show AARD price targets?
Yes. Rallies tracks AARD analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is AARD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AARD. It does not provide personalized investment advice.
AARD

AARD